1 November 2019

TEIPP-targeting immunotherapy project funded by Oncode Institute

Oncode clinical Proof of concept Programme will fund the “TEIPP-targeting immunotherapy” project from Sjoerd van der Burg

Elize Brolsma

Elize Brolsma

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.

Oncode created a clinical Proof-of-Concept fund (cPoC) to support the clinical translation of Oncode’s fundamental research. Together with support from our OEDES team, Clinical Advisory board and Valorization team, Oncode Investigators and their co-workers are developing their research into pre-clinical and clinical projects.

We are pleased to announce that the 7th grant with the cPoC programme has been awarded to Oncode Investigator Sjoerd van der Burg (LUMC), his colleague Thorbald van Hall (LUMC) and pulmonary oncologist Joachim Aerts (Erasmus MC). Together they will develop TEIPP (T-cell epitopes associated with impaired peptide processing)-targeting immunotherapy, a potential anticancer vaccine.

Immunotherapy is an important part of the treatment of some cancers and help the immune system by recognizing and killing cancer cells. Unfortunately, tumors have developed several escape mechanisms, including losing the presentation of T-cell epitopes on cancer cells leading to failure of tumor-reactive T-cells to recognize and kill these tumor cells. Sjoerd and colleagues have developed a vaccine for cancer patients, with the goal to specifically stimulate the immune system to make the cancer cells available again for recognition by the immune cells. After years of fundamental research by them, this project will now be continued in a clinical setting for non-small cell lung cancer.

Other News

Oncode PEP4
(Future) researchers and patients join forces to make true impact
For the second year in a row, Oncode’s Patient Engagement Programme had the opportunity to contribute to the bachelor course ‘Eye for Impact’ for biomedical sciences students at University Medical Center Utrecht (UMCU). A unique example of how to give substance to patient engagement in basic research. Oncode researchers and patient representatives participated in a series of lectures and interactive sessions, where the students experienced first-hand how patients and researchers can partner up.
Jos Jonkers Daniel Zingg website
Unravelling genetic mechanism behind tumor formation can improve targeted treatment
New research by the group of Jos Jonkers explains variation in treatment response to FGFR2 inhibitors and provides a way to improve targeted therapy for cancer patients. Their work highlights the importance of analyzing the functional consequences of genetic variants found in tumors.
Chemotherapy speeds up DNA-level aging
Chemotherapy is an important part of treatment for children with cancer, contributing to the recovery of more and more children. Childhood cancer survivors do sometimes experience late effects from their treatment, including a higher risk of developing a second cancer. That risk is very small, but about five to six times greater than in the ‘normal’ population. In new research, published in Cancer Discovery, the team of Oncode Investigator Ruben Van Boxtel (Princess Máxima Center) shows that accelerated DNA aging turns out to be the main cause of the harmful effect of chemotherapy treatment.